Biotechnology

The innovative software "CAAS vFFR" by Pie Medical Imaging for the non-invasive physiological assessment of intermediate coronary lesions is the subject of FAST III, a multicenter European clinical trial which will investigate the effectiveness of the vessel Fractional Flow Reserve (vFFR) guided revascularization as compared to conventional FFR guided revascularization

MAASTRICHT, Netherlands, Dec. 9, 2021 /PRNewswire/ --  Pie Medical Imaging ("PMI"), a global leader in cardiac imaging, part of the Esaote Group, today announced the beginning of FASTIII, a multicenter randomized clinical trial which willinvestigate the use of angiography-based vessel fractional ...

2021-12-09 21:00 2690

Sciwind Biosciences Completes Enrollment in Phase 2 Clinical Trial of XW003 in Type 2 Diabetes Patients

HANGZHOU, China and SAN FRANCISCO, Dec. 9, 2021 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic disease, today announced the completion of patient enrollment in its Phase 2 clin...

2021-12-09 20:00 2226

Frost & Sullivan Honors Disruptive Organizations in the Region with Prestigious Industry Awards

16 companies will be recognized at the final Frost & Sullivan Virtual Awards Ceremony of the year, which will be broadcasted live on YouTube at6:00 p.m. (GMT +8),16 December 2021. SINGAPORE, Dec. 9, 2021 /PRNewswire/ -- Frost & Sullivan Best Practices Awards will be honoring 16 leading organizat...

2021-12-09 19:32 2178

Lunit Named to the 2021 CB Insights Digital Health 150 -- List of Most Innovative Digital Health Startups

SEOUL, South Korea, Dec. 9, 2021 /PRNewswire/ -- CB Insights today named Lunit to its third annual Digital Health 150 , which showcases the 150 most promising private digital healt...

2021-12-09 11:24 2125

WuXi AppTec Receives 2021 Global Customer Value Leadership Award from Frost & Sullivan

SHANGHAI, Dec. 8, 2021 /PRNewswire/ -- WuXi AppTec, a leading global provider of R&D and manufacturing services that enable the global pharmaceutical and healthcare industry, announced that it is a recipient of the 2021 Global CRDMO Customer Value Leadership Award from Frost & Sullivan, a global ...

2021-12-09 08:00 2118

Treadwell Therapeutics Announces A Presentation at the 2021 SABCS Annual Meeting Featuring a Clinical Trial Update on CFI-402257, a Best-in-Class TTK inhibitor

NEW YORK and HONG KONG, Dec. 8, 2021 /PRNewswire/ -- Treadwell Therapeutics, today announced a presentation for the Company's CFI-402257 program, an oral, best-in-class TTK inhibitor, at the 2021 San Antonio Breast Cancer Symposium (SABCS) being held from December 7-10, 2021.  This presentation w...

2021-12-08 20:00 2436

China's Largest Commercial GMP Plasmid Manufacturing Facility is Put into Operation, GenScript ProBio Expanding Manufacturing Capacity Again

NANJING, China, Dec. 8, 2021 /PRNewswire/ -- On December 7th, the "Opening Ceremony of GenScript ProBio Plasmid Commercial GMP Manufacturing facility and Open Day" was rounded off. GenScript ProBio at the opening ceremony announced thatthe largest commercial GMP plasmid manufacturing facility in ...

2021-12-08 18:22 2232

Nippon Express (Nederland) Acquires GDP Compliance Certification for Company-owned Warehouse

TOKYO, Dec. 8, 2021 /PRNewswire/ -- Nippon Express (Nederland) B.V. (hereinafter "NEN"), a local subsidiary of Nippon Express Co., Ltd., obtained Good Distribution Practice (GDP) certification, effectiveSeptember 6, for its company-owned warehouse in Schiphol Trade Park nearAmsterdam's Schiphol ...

2021-12-08 14:00 1310

GSK Provides Update on Manufacturing Operations in Singapore

SINGAPORE, Dec. 8, 2021 /PRNewswire/ -- GSK announced today that it will cease manufacturing and outsource all production of amoxicillin that is currently produced at its Quality Road site inSingapore. Amoxicillin is an active pharmaceutical ingredient (API) in GSK's Augmentin product. This will ...

2021-12-08 09:30 3745

Henlius' Phase 3 clinical study of novel PD-1 inhibitor serplulimab for the treatment of first-line extensive-stage small cell lung cancer (ES-SCLC) meets primary study endpoint

SHANGHAI, Dec. 8, 2021 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the first interim analysis met the primary study endpoint of the overall survival (OS) of the Phase 3 clinical study (NCT04063163) of its innovative PD-1 inhibitor serplulimab in combination with chemot...

2021-12-08 08:30 2896

CP-COV03, a niclosamide-based oral antiviral drug, under study as possible cure for COVID-19 variants

SUMMARY CP-COV03, a niclosamide-based oral antiviral drug, to cure COVID-19 variants CP-COV03 is a broad-spectrum antiviral drug candidate, developed by Hyundai Bioscience to treat COVID-19. Its active pharmaceutical ingredient is niclosamide, an anthelmintic drug, and is expected to work on var...

2021-12-07 22:00 2263

Global Cord Blood Corporation Announces Results of 2021 Annual General Meeting

HONG KONG, Dec. 7, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"),China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced the results of its 2021 Annual Gene...

2021-12-07 21:35 2516

Global Cord Blood Corporation Announces Results of 2021 Annual General Meeting

HONG KONG, Dec. 7, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"),China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced the results of its 2021 Annual Gene...

2021-12-07 21:32 2573

I-Mab to Pursue Dual Listing Plan on The Main Board of The Stock Exchange of Hong Kong Limited

SHANGHAI and GAITHERSBURG, Md., Dec. 7, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the Board of Directors of the Company (the "Board") ...

2021-12-07 21:00 3231

Sino Biological newly launched a panel of research reagents for SARS-CoV-2 Omicron variant

BEIJING, China, Dec. 7, 2021 /PRNewswire/ -- Sino Biological, Inc. ( http://www.sinobiological.com ; SHE: 301047) announced today that it has launched a panel of research reagents for the newly identified Omicron variant (B.1.1.529) of the SARS-COV-2 virus, which qu...

2021-12-07 18:18 2550

Samsung Biologics adds to global ISO certifications with Quality Management System

* Samsung Biologics earns ISO9001 for Quality Management System, proving its capabilities to ensure high-quality service offerings throughout a product life-cycle * The company is fully certified with the recognition across all of its CDO, CMO and all other core business units in Plant 1,2, a...

2021-12-07 13:04 1624

Akeso Announces Launch of U.S. Investigator-Initiated Study of Cadonilimab (PD-1/CTLA-4 Bispecific Antibody)

HONG KONG, Dec. 6, 2021 /PRNewswire/ -- Today, Akeso, Inc. (9926.HK) announced that the company will support an investigator-initiated study (IIS) to evaluate the efficacy and safety of Akeso's novel, first-in-class anti-PD-1/CTLA-4 bispecific antibody, cadonilimab, for the treatment of neuroendo...

2021-12-07 08:20 1913

Sustainable Superfoods: Sophie's BioNutrients Aims to Replace Soy as a Commercially Viable Protein Alternative within 5 years

SINGAPORE, Dec. 6, 2021 /PRNewswire/ -- Sophie's Bionutrients, a next-generation sustainable urban food production technology company, is shaping the future of food with high moisture extrusion (HME) technology and microalgae fermentation. This process is a revolutionary development in the plant...

2021-12-06 21:06 2560

RedHill Biopharma Reports that Opaganib Mechanism Not Impacted by Viral Spike-Protein Mutations, Including Omicron Mutations

Unique Mode of Action Opaganib works by targeting the human host cell rather than the virus itself and is therefore not expected to be impacted by spike protein mutations, providing a strong rationale for its potential to address the Omicron SARS-CoV-2 variant, as well as other variants of conce...

2021-12-06 20:01 3580

Innoforce Completes Second Tranche of Series A Financing

HANGZHOU, China, Dec. 6, 2021 /PRNewswire/ -- Innoforce ("INF"), a biopharmaceutical manufacturing & development company, announced today the completion of a1 billion CNY ($156.6M) Series A financing, with the closing of an additional375M CNY ($58.7M) following the first tranche of 625M CNY ($96M...

2021-12-06 20:00 2387
1 ... 203204205206207208209 ... 307

Week's Top Stories